• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Steve Jobs: The sickest patient on the waiting list

By
Philip Elmer-DeWitt
Philip Elmer-DeWitt
Down Arrow Button Icon
By
Philip Elmer-DeWitt
Philip Elmer-DeWitt
Down Arrow Button Icon
June 24, 2009, 6:29 AM ET

After three days of ducking the press — and telling the
Wall Street Journal
that Steve Jobs was not listed as a patient there — Methodist University Hospital in Memphis finally admitted Tuesday that Jobs did in fact receive a new liver at their transplant facility.

It the process, the faith-based hospital revealed more than we knew about just how sick Apple’s (AAPL) CEO had been.

With Jobs’ permission, Methodist’s chief transplant surgeon, Dr. James Eason, issued a four paragraph statement designed to counter the impression — apparently widespread — that Jobs had jumped to the top of the transplant waiting list on the strength of his wealth and celebrity.

Judging from our comment stream, most readers believe Jobs’ new liver should have gone to someone who had been waiting longer, needed it more or had a better chance of survival.

Eason flatly denies that. His statement reads, in part:

“Mr. Jobs underwent a complete transplant evaluation and was listed for transplantation for an approved indication in accordance with the Transplant Institute policies and United Network for Organ Sharing (UNOS) policies.

“He received a liver transplant because he was the patient with the highest MELD score (Model for End-Stage Liver Disease) of his blood type and, therefore, the sickest patient on the waiting list at the time a donor organ became available. Mr. Jobs is now recovering well and has an excellent prognosis.”

This is revealing.

MELD is the numerical measure used by transplant centers to assess the severity of chronic liver disease. It was developed to predict the odds that a patient will die within three months based on a scoring system that ranges from less than 10 (4% mortality) to 40 or more (100% mortality).

The MELD algorithm takes values from the patient’s blood and urine tests and spits out an answer. In a hospital’s computer, it looks like this:



Where

  • INR, or international normalized ratio for prothrombin time, is a measure of how fast the patient’s blood clots
  • Bilirubin levels tell doctors how well the patient’s liver is functioning
  • Creatinine levels provide a measure of the patient’s kidney function
  • Dialysis treatments, which do the work of the kidneys, affect creatinine readings

We don’t know whether Steve Jobs was getting dialysis twice a week, but if his MELD score was higher than every other liver transplant candidate with his blood type in Tennessee — which has a relatively short waiting list but still averages 48 days — he was very sick indeed.

Jobs had a cancerous tumor removed from his pancreas in 2004 and went on a medical leave January to deal with continuing health issues that he initially described as an easily treated hormone imbalance.

Although he was spotted on Apple’s Cupertino, Calif., campus Monday, his spokespeople continue to say only that Jobs looks forward to returning to Apple at the end of June.

See also:

  • Inside Steve Jobs’ liver transplant
  • Why does Steve Jobs look so thin?
  • Steve Jobs takes a medical leave
  • Steve Jobs, chained to a rock
About the Author
By Philip Elmer-DeWitt
See full bioRight Arrow Button Icon

Latest in

CryptoBinance
Binance has been proudly nomadic for years. A new announcement suggests it’s finally chosen a headquarters
By Ben WeissDecember 7, 2025
3 hours ago
Big TechStreaming
Trump warns Netflix-Warner deal may pose antitrust ‘problem’
By Hadriana Lowenkron, Se Young Lee and BloombergDecember 7, 2025
7 hours ago
Big TechOpenAI
OpenAI goes from stock market savior to burden as AI risks mount
By Ryan Vlastelica and BloombergDecember 7, 2025
7 hours ago
InvestingStock
What bubble? Asset managers in risk-on mode stick with stocks
By Julien Ponthus, Natalia Kniazhevich, Abhishek Vishnoi and BloombergDecember 7, 2025
7 hours ago
EconomyTariffs and trade
Macron warns EU may hit China with tariffs over trade surplus
By James Regan and BloombergDecember 7, 2025
7 hours ago
EconomyTariffs and trade
U.S. trade chief says China has complied with terms of trade deals
By Hadriana Lowenkron and BloombergDecember 7, 2025
7 hours ago

Most Popular

placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
1 day ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
1 day ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
3 days ago
placeholder alt text
Politics
Supreme Court to reconsider a 90-year-old unanimous ruling that limits presidential power on removing heads of independent agencies
By Mark Sherman and The Associated PressDecember 7, 2025
15 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.